8 results
424B5
HARP
Harpoon Therapeutics Inc
16 May 23
Prospectus supplement for primary offering
6:09am
statements include statements regarding:
the timing of the initiation, progress, safety profiles, expected results and any wind downs of our preclinical
8-K
EX-99.1
HARP
Harpoon Therapeutics Inc
11 May 23
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
9:07pm
-related costs due to corporate restructuring implemented in November 2022 and lower clinical and development costs due to the wind down of the HPN424
- Prev
- 1
- Next